Prospective, randomized, double-blind, placebo-controlled, multicenter study to investigate the efficacy and safety of NT 201 in the treatment of lower limb spasticity caused by stroke or traumatic brain injury in adult subjects, followed by an open label extension with or without combined upper limb treatment - M602011014

Merz Pharmaceuticals GmbH0 个研究点目标入组 445 人开始时间: 2024年7月5日最近更新: 2024年8月21日

适应症

试验速览

暂无简介。

•Female or male subject = 18 years and = 85 years at screening, Diagnosis of lower limb spasticity with or without upper limb spasticity of the same body side caused by stroke or traumatic brain injury, Disabling ankle flexor spasticity presenting as pes equinus or pes equinovarus, Modified Ashworth Scale-Bohannon [MAS] score of 2 or 3 points in the ankle plantar flexor of the target lower limb (supine position, knee extended), Minimum passive range of motion in ankle of the target lower limb (supine position, knee extended): 10°dorsiflexion and 20°plantarflexion, At least 4 months since last botulinum neurotoxin [BoNT] injection for treatment of spasticity or any other condition, For subjects receiving anticoagulation therapy, the investigator confirms and documents that the subject has an: o Activated partial thromboplastin time [aPTT] = 80 seconds (subjects on dabigatran or other direct thrombin inhibitors) or o International normalized ratio [INR] value of = 2.5 (subjects on coumarins or other anticoagulants monitored by INR).

•Generalized disorders of muscle activity (e.g., myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis) or any other significant peripheral neuromuscular dysfunction which might interfere with the study, Subjects with presence or history of aspiration pneumonia, recurrent lower respiratory tract infections, or compromised respiratory function as per investigator's clinical judgment, Pregnancy (as verified by a positive pregnancy test) or breast feeding., Bilateral lower limb paresis/paralysis/spasticity or tetraparesis/paralysis/spasticity, Body weight < 50 kg, Severe atrophy of the target limb muscles, Previous, ongoing or planned treatments of spasticity with intrathecal baclofen, Previous, ongoing, or planned treatments of spasticity in the target lower limb with any of the following procedures: o Surgical intervention o Alcohol or phenol block o Muscle afferent block, Physiotherapy or use of orthoses or splints at the target limb initiated less than 4 weeks before screening or expected to change during the double-blind phase of the study, Current or planned treatment with parenterally administered drugs that interfere with neuromuscular transmission (e.g., intrathecal baclofen, tubocurarine-type muscle relaxants used in anesthesia), or local anesthetics in the treated region within 2 weeks prior to screening, Infection or inflammation at the injection sites

发起方